Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605092 | 0.94 | KDM4E (0.50) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL6039643 | 0.92 | KDM4E (0.49) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL8259566 | 0.86 | HTR1A (0.55) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL19049402 | 0.84 | KDM4E (0.50) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL2649295 | 0.82 | KDM4E (0.46) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL6765965 | 0.82 | SIGMAR1 (0.61) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL12932756 | 0.81 | KDM4E (0.48) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL11608912 | 0.80 | SIGMAR1 (0.66) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL2649407 | 0.80 | KDM4E (0.50) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL2650435 | 0.80 | KDM4E (0.50) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | KDM4E 2989/4885MDM2 2785/4885ALDH1A1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.